Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Klaudia Urrutia-Pérez et al.|EClinicalMedicine|2022Cited by 69
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)Zurina Cinza-Estévez, Y. RodriguezGuevara, Sonia Resik et al.|EClinicalMedicine|2023Cited by 6
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Maria C. Ricardo-Cobas, Yenima Martín‐Bauta et al.|medRxiv|2021Cited by 3
A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trialIdelsis Esquivel-Moynelo, Iraldo Bello Rivero, Jesus Perez-Escribano et al.|Annals of Antivirals and Antiretrovirals|2021Cited by 2